Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 327-337-Neuroendocrine Tumors
Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-331
Donato Iacovazzo*1, Francesca Lugli1, Francesca Plastino1, Rosalba Barile1, Giovanni Schinzari1, Antonio Bianchi1, Guido Rindi1, Alfredo Pontecorvi2, Laura De Marinis2 and Carlo Antonio Mario Barone1
1Catholic University, Rome, Italy, 2Catholic University School of Medicine, Rome, Italy
Introduction: everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.

Matherials and methods: we treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, progressive, low or intermediate-grade NETs for a mean period of 11 months. Somatostatin analogues treatment was continued in all patients. 12/14 patients had previously undergone Peptide Receptor Radionuclide Therapy (PRRT). 

Results: according to RECIST criteria, stable disease was observed in 9/14 patients and partial response was achieved in 2/14 patients. Median progression-free survival was 12.0 months. Drug-related adverse events included stomatitis (7/14), hyperglycaemia (7/14), hypertriglyceridemia (5/14), pneumonitis (4/14), hematologic toxicity (4/14), peripheral oedema (4/14) and rash (2/14). Grade 3 and 4 adverse events included pneumonitis (3 cases) and thrombocytopenia (2 cases). Dose reduction was required in 5/14 patients.

Conclusion: our data confirm the efficacy of everolimus in the treatment of progressive, advanced NETs. The apparently higher rate of grade 3 and 4 adverse events is probably related to the high proportion of patients in our series that had previously undergone PRRT, as it may enhance everolimus potential mielotoxicity.

Nothing to Disclose: DI, FL, FP, RB, GS, AB, GR, AP, LD, CAMB

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm